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Abstract
Background: To assess the importance of heredity in the etiology of inflammatory breast cancer (IBC), we
compared IBC patients to several carefully chosen comparison groups with respect to the prevalence of first-degree
family history of breast cancer.
Methods: IBC cases (n = 141) were compared to non-inflammatory breast cancer cases (n = 178) ascertained
through George Washington University (GWU) with respect to the prevalence of first-degree family history of breast
cancer and selected environmental/lifestyle risk factors for breast cancer. Similar comparisons were conducted with
subjects from three case–control studies: breast cancer cases (n = 1145) and unaffected controls (n = 1142) from the
Cancer Genetic Markers of Susceptibility (CGEMS) study, breast cancer cases (n = 465) and controls (n = 9317) from
the Women’s Health Initiative (WHI) study, and ovarian cancer cases (n = 260) and controls (n = 331) from a study by
University of Toronto (UT).
Results: The frequency of first-degree breast cancer family history among IBC cases was 17.0 % compared to 24.
4 % for GWU breast cancer cases, 23.9 % and 17.9 % for CGEMS breast cancer cases and controls, respectively, 16.
9 % and 12.6 % for WHI breast cancer cases and controls, respectively, and 24.2 % and 11.2 % for UT ovarian cancer
cases and controls, respectively.
IBC cases had a significantly lower prevalence of parous women than WHI breast cancer cases (OR = 0.46, 95 % CI:0.
27–0.81) and controls (OR = 0.31, 95 % CI:0.20–0.49). Oral contraceptive use was significantly higher among IBC
cases compared to WHI breast cancer cases (OR = 7.77, 95 % CI:4.82–12.59) and controls (OR = 8.14, 95 % CI:5.28–12.
61). IBC cases had a significantly higher frequency of regular alcohol consumption (≥1 drink per day) compared to
WHI controls (OR = 1.84, 95 % CI:1.20–2.82) and UT controls (OR = 1.86, 95 % CI:1.07–3.22) and higher (statistically
non-significant) prevalence (21.3 %) compared to breast cancer cases from GWU (18.2 %) and WHI (15.2 %).
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Conclusions: The prevalence of first-degree breast cancer family history among IBC cases was lower compared to
breast and ovarian cancer cases but higher than unaffected individuals. Our multiple-case inflammatory and
non-inflammatory breast cancer families may reflect aggregation of common genetic and/or environmental factors
predisposing to both types of breast cancer. Our findings that oral contraceptive use and regular alcohol consumption
may be associated with IBC warrant further investigations.
Keywords: Inflammatory breast cancer, IBC, Heredity, Case-comparison study, Family history of breast cancer, Breast
cancer risk factors, Multiplex IBC families
Background
Inflammatory breast cancer (IBC) is a rare form of
breast cancer characterized by an early average age of
diagnosis (52 years versus 57 years for non-inflammatory
breast cancer), aggressive histopathologic features (at
least stage IIB at diagnosis), and poor survival [1]. Clin-
ically, IBC is defined by the American Joint Committee
on Cancer (AJCC) as a disease characterized by redness,
warmth and edema (peau d’orange) involving at least
one-third of the breast [2]. IBC accounts for an esti-
mated 1.0 %-5.0 % of all incident breast carcinomas and
8.0–10.0 % of breast cancer mortality [3–5]. Variable
incidence trends of IBC have been reported in various
geographic areas and among different ethnic/racial
groups, with increasing trends reported in the United
States [4–6] and decreasing trends in Tunisia [7].
The etiologic components of IBC are generally
unknown and the contributions of hereditary versus
environmental/life style factors remain subject of contro-
versy in the literature. Case reports and case-case studies
of IBC have reported associations with factors such as
early age at first birth [8, 9], high body mass index
(BMI) [10, 11], trauma [12], and longer duration of
breast feeding (hypothesized to increase risk through an
estrogen surge) [9]. Reports of IBC clusters [8, 13], sea-
sonal variations in the risk of IBC [14], higher occur-
rence in rural versus urban settings [15], and declining
incidence with improving socioeconomic status [7] fur-
ther highlight the role of environmental factors in the
etiology of IBC. On the other hand, reports of familial
IBC, including in association with BRCA mutations [16]
suggest a role for heredity. Furthermore, genetic influ-
ences play a role in susceptibility to other malignancies
with a major environmental component, such as lung
and colorectal cancers [17–20].
In order to investigate the importance of hereditary
factors in the etiology of IBC, we compared patients
with IBC to several carefully chosen comparison groups
with known prevalence of first-degree breast cancer fam-
ily history. These comparison groups consisted of
population-based and hospital-based non-inflammatory
breast cancer and ovarian cancer cases as well as healthy
controls (with no personal history of breast or ovarian
cancer). As a secondary objective, comparisons were also
made with respect to selected environmental/lifestyle
risk factors for breast cancer.
Methods
Subject ascertainment and secondary data requisition
Patients with IBC (n = 141) and with non-inflammatory
breast cancer (n = 178) were ascertained through epi-
demiologic studies conducted at George Washington
University (GWU) from 2002 to 2012 [11, 21]. All
subjects were Caucasian and the same epidemiologic
questionnaire asking about reproductive, medical and
family history was collected on both groups of pa-
tients at the time of recruitment. The family history
portion of the questionnaire asked about diagnosis of
breast cancer among first-degree relatives of the index
case. We subsequently validated the family history
questions of this questionnaire by collecting pedigrees
on 21 of 67 living IBC patients and by correlating the
information from pedigrees and the questionnaires.
We found 100 % agreement between the two modes
(questionnaire versus pedigree) of collecting first-
degree breast cancer family history information. We
also came across several families with cases of both
inflammatory and non-inflammatory breast cancer
among the relatives.
We compared the IBC cases with breast cancer cases
and controls recruited through two large population-
based studies, which were available to us as secondary
datasets. Raw data from the Cancer Genetic Markers of
Susceptibility (CGEMS) [22, 23] and the Women’s
Health Initiative (WHI) [24, 25] cohorts were down-
loaded from the National Institutes of Health (NIH),
database for Genotypes and Phenotypes (dbGaP) after
obtaining approvals from the corresponding data reposi-
tory committees at the NIH/dbGaP. All CGEMS and
WHI subjects in our study were Caucasian; additional
information about these secondary datasets is provided
below.
Post-menopausal breast cancer cases unselected for age
or family history (n = 1145) along with appropriately-
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matched healthy controls with no personal history of
breast cancer (n = 1142) were available from the CGEMS
breast cancer study [dbGaP accession #6175-10, version
phs000147/GRU] nested within the Nurses’ Health Study
(NHS) cohort [22, 23]. The CGEMS breast cancer cases
and controls were compared to IBC cases with respect to
the prevalence of first-degree breast cancer family history.
Information on environmental risk factors on the CGEMS
breast cancer cases and controls was not made available
to us as part of the secondary data, therefore, comparisons
with CGEMS were limited to the family history data.
Another group of post-menopausal breast cancer cases
(≥50 years of age) unselected for family history (n = 465)
and healthy controls with no personal history of breast
or ovarian cancer (n = 9317) was obtained from the
Hormone Therapy Trials of the WHI cohort [dbGaP
accession #11296-6 for version phs000200/HMB-IRB-
NPU and #11295-7 for version phs000200/HMB-IRB]
[24, 25]. WHI cases and controls were compared to IBC
cases with respect to the prevalence of first-degree
breast cancer family history and selected environmental
risk factors for breast cancer.
Given that many genetic and environmental risk fac-
tors for breast cancer also predispose to ovarian cancer
[26] and that first-degree family history of breast cancer
is a significant risk factor for ovarian cancer as well [26],
we conducted similar comparisons with subjects who
had been ascertained through a case–control study of
ovarian cancer conducted at the University of Toronto
(UT) and available to us as secondary data. The UT
study had ascertained Ashkenazi Jewish women with
ovarian cancer (n = 260, unselected for age or family his-
tory) and appropriately-matched controls (n = 331, with
no personal history of ovarian cancer) from several
hospitals in North America [27]. Detailed epidemiologic
and family history information was collected at the time
of ascertainment through structured interviews, the
majority of which were conducted by RM. The main
objectives of the UT ovarian cancer study were to deter-
mine the role of genetic and environmental risk factors
and to characterize the BRCA genes [27, 28]. Genetic
analysis as part of the original UT study had identified
96 carriers of the three BRCA Ashkenazi Jewish founder
mutations (51 BRCA1 185delAG, 15 BRCA1 5382insC,
and 30 BRCA2 6174delT carriers) and 164 non-carriers
[27, 28].
Statistical analysis
IBC cases were compared to breast and ovarian cancer
cases and healthy controls with respect to the prevalence
of first-degree family history of breast cancer and se-
lected environmental/lifestyle risk factors for breast can-
cer. The environmental/lifestyle variables were selected
based on availability of information on each variable
from the majority of datasets and included parity, body
mass index (BMI), regular alcohol use (≥1 drink per
day), and ever use of oral contraceptives. CGEMS breast
cancer cases and controls were only used for comparison
of family history since information about environmental/
lifestyle variables was not made available to us as part of
the secondary data on these subjects. Unadjusted Odds
ratios and 95 % confidence intervals were calculated. For
the primary objective of comparing first-degree breast
cancer family history, adjusted analyses (controlling for
age, parity, BMI, regular alcohol use and ever use of oral
contraceptives) were also conducted for comparison of
GWU IBC and non-IBC cases. All statistical analyses
were conducted using SAS version 9.1 (SAS Institute,
Cary, NC) and Epi Info™ (http://www.cdc.gov/epiinfo).
Results
Average age of diagnosis for IBC cases (48.3 years)
was lower than that of non-inflammatory breast cancer
cases from GWU (51.8 years) and WHI (73.6 years) as
well as ovarian cancer cases (56.1 years) (Table 1). Average
age of diagnosis for CGEMS breast cancer cases was not
available but the investigators reported all cases to be
post-menopausal at diagnosis [22]. Average age at study
entry for CGEMS subjects was estimated from ranges pro-
vided as part of the secondary data (Table 1). Older aver-
age ages of diagnosis for WHI breast cancer cases reflect
the postmenopausal inclusion criteria and the prospective
study design of the WHI trials.
First-degree breast cancer family history was defined
as the presence of at least one case of breast cancer
among the mothers and/or sisters of the index cases.
The prevalence of first-degree breast cancer family
history among the IBC cases (17.0 %) was lower in
comparison to the prevalence among the non-
inflammatory breast cancer cases from GWU (24.4 %),
breast cancer cases from CGEMS (23.9 %), and ovarian
cancer cases irrespective of the BRCA mutation status
(24.2 %) (Table 1). Comparisons revealed nearly similar
frequency of first-degree family history of breast cancer
among IBC cases compared to WHI breast cancer cases
(16.9 %), BRCA-negative ovarian cancer cases (18.3 %),
and CGEMS controls (17.9 %), and higher prevalence
compared to UT-controls (11.2 %) and WHI controls
(12.6 %) (Table 1). None of the comparisons involving
family history reached statistical significance; adjusted
analyses of GWU data produced similar odds ratios
to unadjusted analyses. These results suggest a lower
or similar prevalence of first-degree breast cancer
family history among IBC cases compared to hospital-
based and population-based breast and ovarian cancer
cases but higher prevalence compared to unaffected
individuals.
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Table 1 Hereditary and Selected Environmental Risk Factors among Inflammatory Breast Cancer Cases and Comparison Groups
GWU IBCa
Cases
GWU BCa
Cases
UT OCb
Cases
OC Casesc
BRCA
OC Casesd
non-BRCA
UTb
Controls
WHI BCe
Cases
WHIe
Controls
CGEMS BCf
Cases
CGEMSf
Controls
n = 141 (%) n = 178 (%)g n = 260 (%) n = 96 (%) n = 164 (%) n = 331 (%) n = 465 (%)g n = 9317
(%)g
n = 1145 (%) n = 1142 (%)
Average Age at Study Entry 50.3 53.8 59.2 57.9 60.1 52.2 67.0 67.0 65.4h 65.6h
Average Age at Diagnosis 48.3 51.8 56.1 54.6 57.1 NA 73.6 NA Unavailablei NA
Average Body Mass Index (Kg/m2) 28.9 26.5 24.5 24.3 24.5 24.9 30.2 28.8
First-Degree Breast Cancer Family History
Yes 24 (17.0) 43 (24.4) 63 (24.2) 33 (34.4) 30 (18.3) 37 (11.2) 74 (16.9) 1105 (12.6) 274 (23.9) 204 (17.9)
Parity (≥1 Pregnancy)
Yes 114 (80.9) 130 (73.9) 233 (89.6) 89 (92.7) 144 (87.8) 286 (86.4) 418 (90.1) 8661 (93.1)
Oral Contraceptive Use
Yes 113 (80.1) 125 (71.0) 101 (38.8) 43 (44.8) 58 (35.4) 216 (65.3) 159 (34.2) 3089 (33.1)
Regular Alcohol Use (≥1 drink per day)
Yes 30 (21.3) 32 (18.2) 35 (13.5) 16 (16.7) 19 (11.6) 42 (12.7) 69 (15.2) 1184 (12.8)
a Inflammatory breast cancer (IBC) and non-inflammatory breast cancer (BC) cases recruited at George Washington University (GWU). All subjects recruited at GWU and included in this study were Caucasian. Subjects
were recruited within an average of two years post diagnosis
b Ovarian Cancer (OC) cases and controls obtained from hospital-based case–control study conducted at University of Toronto (UT). All subjects recruited through the UT study were Caucasian and Ashkenazi Jewish
c Ovarian cancer cases with an Ashkenazi Jewish founder mutation in the BRCA1 (185delAG and 5382insC) and BRCA2 (6184delT) genes
d Ovarian cancer cases who tested negative for the three Ashkenazi Jewish founder mutations in the BRCA1 or BRCA2 genes
e Breast cancer (BC) cases and controls obtained from the Hormone Therapy Trials of the population-based Women’s Health Initiative (WHI) cohort. All WHI cases and controls included in our study were Caucasian and
50 years of age or above at study entry
f Breast Cancer (BC) cases and controls obtained from the Cancer Genetic Markers of Susceptibility (CGEMS) study conducted among participants in the population-based Nurses’ Health Initiative (NHS) cohort. All
subjects in CGEMS were Caucasian and post-menopausal at recruitment
g Percentages for some variables do not correspond to the total number of cases and controls due to “missing” answers
h Estimated from age ranges provided as part of the secondary data as follows: <54, 55–59, 60–64, 65–69, 70–74, and ≥75
i Average age of diagnosis was unavailable but all cases were reported to be post-menopausal at diagnosis and controls were matched to cases based on several criteria including age at diagnosis
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We identified several multiplex IBC families. The IBC
index case in one family had a mother, a paternal aunt,
and a paternal uncle with breast cancer. The disease was
pre-menopausal in one relative and a paternal cousin
was reported to have died from ovarian cancer at age 30.
The index case in another family reported a sister and
two aunts with breast cancer, including one with pre-
menopausal disease. Another family was notable for
reported pre- and peri-menopausal breast cancer in two
sisters of the index case and a maternal relative diag-
nosed in her late 30’s. To our knowledge, these are
among the first reported families with multiple cases of
non-inflammatory breast cancer among first- and
second-degree relatives of the IBC index case.
Body mass index (BMI) is considered a risk factor for
both IBC [10] and for non-inflammatory breast cancer
(post-menopausal only) [29]. BMI for IBC cases in our
study (28.9 kg/m2) was slightly higher than the BMI of
breast cancer cases from GWU (26.5 kg/m2) and of
ovarian cancer cases and controls (24.5 kg/m2 and
24.9 kg/m2, respectively) (Table 1) but the comparisons
did not reach statistical significance. WHI breast cancer
cases had higher BMI (30.2 kg/m2) compared to all
other groups including the IBC cases, but comparisons
did not reach statistical significance.
Nulliparity is a risk factor for both non-inflammatory
breast cancer [30] and ovarian cancer [26] but has not
been reported in association with the risk of IBC. IBC
cases in our study had a higher prevalence of parous
women (80.9 %) compared to non-inflammatory breast
cancer cases from GWU (73.9 %) but the comparison did
not reach statistical significance. The prevalence of parous
women among IBC cases was significantly lower than the
prevalence among WHI breast cancer cases (OR = 0.46,
95 % CI: 0.27–0.81) and WHI controls (OR = 0.31, 95 %
CI: 0.20–0.49) as well as the prevalence among ovarian
cancer cases (OR = 0.49, 95 % CI: 0.26–0.91).
Long-term use (>10 years) of oral contraceptives has
been associated with an increased risk for non-
inflammatory breast cancer [31] and its short-term use
is believed to reduce the risk of ovarian cancer [32, 33].
Oral contraceptive use has not been previously reported
in association with the risk of IBC. Data on duration of
oral contraceptive use was not available on some of the
comparison groups in our study and hence we limited
our comparisons to ever use of oral contraceptives. The
prevalence of ever use of oral contraceptives among IBC
cases (80.1 %) was significantly higher compared to
WHI breast cancer cases (OR = 7.77, 95 % CI: 4.82–
12.59) and controls (OR = 8.14, 95 % CI: 5.28–12.61).
IBC cases also reported a significantly higher ever use of
oral contraceptives compared to ovarian cancer cases
(OR = 6.35, 95 % CI: 3.83–10.62) and controls (OR =
2.15, 95 % CI: 1.31–3.54) from UT. The higher
prevalence of oral contraceptive use among IBC cases in
comparison to non-inflammatory breast cancer cases
from GWU was of borderline statistical significance
(OR = 1.71, 95 % CI: 0.98–2.99).
Excess alcohol consumption (>35 g per day) is an
established risk factor for non-inflammatory breast
cancer [34–37] but has not been previously reported in
association with the risk of IBC. In our study, IBC cases
had significantly higher prevalence of regular alcohol use
(≥1 drink per day) compared to WHI controls (OR =
1.84, 95 % CI: 1.20–2.82) and UT controls (OR = 1.86, 95
% CI: 1.07–3.22). Of note, the prevalence of regular
alcohol use was higher among IBC cases (21.3 %) com-
pared to non-inflammatory breast cancer cases from
GWU (18.2 %) and from WHI (15.2 %) (Table 1) but the
difference did not reach statistical significance. The asso-
ciation between alcohol intake and increased risk of IBC
needs further investigation in future studies.
Discussion
We undertook this study to assess the importance of
heredity in the etiology of IBC because of the many re-
ports emphasizing the strong impact of the environment
on IBC [7–9, 11–15]. We compared the prevalence of
breast cancer among first-degree relatives (i.e., mothers
and sisters) between IBC cases and several comparison
groups chosen to represent case and control groups with
a range of high and low prevalence of first-degree breast
cancer family history. Breast cancer and ovarian cancer
patients are expected to have a high prevalence of first-
degree breast cancer family history [38, 39] while healthy
individuals with no personal history of breast or ovarian
cancer are expected to have a lower prevalence [40].
Our comparisons revealed that IBC cases in our study
had a slightly lower or similar prevalence of first-degree
breast cancer family history compared to breast and
ovarian cancer patients but a higher prevalence com-
pared to unaffected controls.
Up to twenty percent of breast cancer cases are be-
lieved to be hereditary (characterized by multiple cases
of breast and/or other cancers among relatives) and due
to segregation of high-penetrance [i.e., relative risk (RR)
= 20)] susceptibility genes in the affected families [41].
Ovarian cancer has the highest rate of hereditary inci-
dence world-wide; current estimates put the percentage
of hereditary cases at 20 % of all cases of this disease
[42]. Besides age, a family history of breast and ovarian
cancer is the most significant risk factor for ovarian can-
cer [42]. Mutations in the breast and ovarian cancer sus-
ceptibility genes, BRCA1 and BRCA2, are responsible for
the majority of hereditary cases of breast cancer [41]
and ovarian cancer [42]. In addition to the genetic link
between breast and ovarian cancers, there are several
shared environmental risk factors which predispose to
Moslehi et al. BMC Cancer  (2016) 16:334 Page 5 of 9
both conditions [26]. Therefore, ovarian cancer was con-
sidered a suitable case group for comparison with IBC.
The prevalence of breast cancer among first-degree
relatives of both breast and ovarian cancer cases in our
study was between 16.9 % and 24.4 %, which is within
the range reported in the literature (i.e., 6.2 %-27.1 % for
general breast and ovarian cancer cases irrespective of
BRCA mutation status [27, 28, 43–45]). Thus, IBC cases
had slightly lower prevalence of first-degree breast can-
cer family history than the breast and ovarian cancer
cases (irrespective of BRCA carrier status) in our study
but a slightly higher prevalence than general breast and
ovarian cancer cases in some studies reported in the lit-
erature. A recent nested case–control study in the Breast
Cancer Surveillance Consortium (BCSC) investigated
the association between IBC risk and number of factors,
including family history of breast cancer. This study also
found a higher risk of IBC in association with first-
degree family history of breast cancer [46]. An earlier
study had reported a 20 % frequency of breast cancer
family history among IBC cases [47].
The prevalence of first-degree breast cancer family his-
tory among UT controls (11.2 %) and WHI controls
(12.6 %) was slightly higher than the range (4.8–7.3 %)
of estimates reported in the literature for healthy women
with no personal history of breast or ovarian cancer [43,
45]. The even higher estimates for CGEMS controls
(17.9 %) may reflect a particular aspect of the study
design or subject characteristics of the CGEMS genome-
wide association study [22]. Nonetheless, the prevalence
of first-degree breast cancer family history among the
IBC cases was higher than the prevalence among healthy
individuals from the UT and WHI studies as well as the
prevalence estimates reported in the literature.
We identified several IBC cases with non-inflammatory
breast cancer and other cancers among first- and second-
degree relatives, as discussed in the previous section.
Three families with multiple cases of IBC were also identi-
fied in our study; one index case had a daughter with IBC,
one had a sister with IBC and the third had a cousin with
IBC. A case report of hereditary IBC in a mother and a
daughter had identified a deleterious BRCA2 mutation re-
sponsible for the disease in that family [16]. Accurate esti-
mates of BRCA mutation frequency among IBC cases
from systematic studies remain to be reported. Our results
indicate that a proportion of IBC cases occur in the con-
text of familial breast cancer which may be explained by
aggregation of common hereditary factors and/or shared
environmental risk factors predisposing to both inflamma-
tory and non-inflammatory breast cancer in these families.
Our findings and the previous case report of hereditary
IBC highlight the importance of obtaining pedigrees on
IBC cases and noting all diagnoses of cancer and benign
disease among the relatives.
As part of this study, we also conducted comparisons
between IBC and other groups with respect to the
prevalence of selected environmental/life style risk fac-
tors for breast cancer, such as parity, BMI, oral contra-
ceptive use, and consumption of alcoholic beverages.
These comparisons were secondary to the main study
objective and the secondary nature of some of the com-
parison groups was a limitation with respect to the abil-
ity to conduct a comprehensive analysis of all relevant
environmental/lifestyle factors. Therefore, our findings
with respect to the selected environmental/life style
factors need to be interpreted with caution. Our com-
parisons revealed a higher prevalence of nulliparity, oral
contraceptive use and regular alcohol consumption (≥1
drink on daily basis) among IBC cases.
The prevalence of ever use of oral contraceptives was
significantly higher among IBC cases (80.1 %) compared
to all other comparison groups including breast cancer
and ovarian cancer cases in our study. The differences
between groups with respect to oral contraceptive use
may be due to differences in age or other confounding
factors between groups. Therefore, the association be-
tween oral contraceptive use and IBC risk needs further
investigation in future studies accounting for all poten-
tial confounding variables. We had previously reported
associations between aggressive (high-grade) breast can-
cer with long-term oral contraceptive use [11].
Our findings with respect to the association
between alcohol consumption and IBC are also novel.
The prevalence of regular alcohol use (≥1 drink per
day) was higher among IBC cases compared to all
other comparison groups in our study. These findings
are particularly noteworthy given that excess alcohol
consumption (>35 g per day) is an established risk
factor for non-inflammatory breast cancer [34–37].
Ethanol and acetaldehyde have been classified as
group I carcinogens (i.e., carcinogenic to humans) by
International Agency for Research on Cancer (IARC)
and are believed to be the carcinogenic components
of alcohol [37]. IARC classification is based on
sufficient evidence in humans for carcinogenicity of
alcohol consumption as demonstrated from case–con-
trol, cohort and mechanistic studies [48]. Carcino-
genic components of alcohol may exert their effects
directly through inducing genetic or epigenetic muta-
tions or indirectly through inducing inflammatory
processes [48]. The role of inflammatory processes in
IBC development is not known. A number of markers
of inflammation such as NF-kB, Cox, and JAK/STAT
signaling have been suggested to play a role in the
tumorigenesis of IBC [49]. Inflammation may contribute
to IBC development through promoting proliferation, cre-
ating a pro-inflammatory tumor microenvironment, and/
or promoting metastasis of malignant cells [49].
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As mentioned earlier, the secondary nature of some of
the comparison groups is a limitation of our study,
particularly with respect to analysis of environmental/life
style factors. Strengths of our study include systematic
data collection through the use of epidemiologic
questionnaires on all case and control groups; the exact
same questionnaire was used on the IBC and non-
inflammatory breast cancer cases from GWU. Other
strengths include validation of the family history-related
questions through collection of detailed pedigrees on a
subset of IBC cases and access to raw (secondary) data
from several case–control studies, which could be used
as additional comparison groups. The case–control
comparison groups in our study were sufficiently large
to allow statistically meaningful comparisons and the
unaffected individuals used as controls in these studies
were appropriately matched to the breast and ovarian
cancer cases on important criteria such as age and
ethnicity.
Conclusion
In summary, our study found the prevalence of first-
degree family history of breast cancer among IBC cases
to be slightly lower or similar compared to breast and
ovarian cancer cases but higher than unaffected individ-
uals. Therefore, similar contribution of hereditary
components to IBC risk as that to non-inflammatory
breast cancer risk cannot be ruled out. Our findings of
multiple-case inflammatory and non-inflammatory
breast cancer families may further reflect aggregation of
genetic factors and gene-environment interactions pre-
disposing to both types of breast cancer. Our findings
that oral contraceptive use and regular alcohol con-
sumption may increase the risk of IBC are noteworthy
due to modifiable nature of these potential risk factors.
Collection of multi-generation pedigrees and detailed
epidemiologic information noting the factors associated
with an increased risk of IBC in studies by us and others
will help decipher the etiologic role of hereditary and
environmental factors in susceptibility to IBC in future
studies. Because of the rarity of IBC and multiplex IBC
families, the importance of developing consortia to
enable epidemiologic investigations including gene-
environment interaction studies should be emphasized.
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